A Single-dose Cross-over Study to Assess Direct and Indirect Effects of Dapagliflozin on Pancreatic Alpha and Beta Cells in Patients With Type 2 Diabetes

Status:
Completed

Trial end date:
2016-12-01

Target enrollment:

Participant gender:

The purpose of this study is to evaluate if Dapagliflozin has direct effect on alpha cell glucagon release.

Phase 4

Uppsala University

AstraZeneca

Dapagliflozin
Saxagliptin